Walvax COVID-19 vaccine
Vaccine description | |
---|---|
Target disease | SARS-CoV-2 |
Type | ? |
Clinical data | |
Routes of administration |
Intramuscular |
Identifiers | |
DrugBank | DB15855 |
Lua error in package.lua at line 80: module 'strict' not found. ARCoV, also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine candidate developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science.[1] It is in Phase III trials in Mexico.[2]
Contents
Description
ARCoV is an mRNA vaccine which consists of lipid nanoparticle–encapsulated mRNA encoding the receptor binding domain of SARS-CoV-2. It was the first mRNA vaccine to be approved for clinical trials in China. Manufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week.[1] Reuters later reported that it can be stored at (2–8 °C) for six months.[2]
Scrips noted that Abogen created its own solid lipid nanoparticle to deliver the vaccine.[3]
Development
Phase I and II trials
Preclinical studies in mice and primates have shown ARCoV elicited a Th1-biased cellular response and robust antibodies against SARS-CoV-22.[1][4]
In June 2020, Walvax began a Phase I trial to evaluate safety, tolerance, and preliminary immunogenicity with 168 participants aged 18–59 in Hangzhou divided into low-dose, medium-dose, and high-dose groups.[5]
In January 2021, Walvax began a Phase II trial to evaluate immunogenicity and safety of different doses with 420 participants aged 18–59 in Yongfu and Xiangfen divided into low-dose, medium-dose, high-dose, and placebo groups.[6]
Phase III trials
The Phase III trials would enroll an estimated 28,000 participants. Elderly people over 60 years old are planned to comprise 25% of trial participants and randomly assigned into the study group and control group at a ratio of 1:1.[7] Tigermed, a Hangzhou-based clinical research organization, would be responsible for conducting the overseas trials. If successful, production of ARCoV could start in early 3rd quarter 2021.[8]
Reuters reported that Phase III trials in Mexico would involve 6,000 people and start by May 2021.[2] In 2020, Walvax had previously expressed an interest in making the vaccine in Mexico.[9]
Colombia, Indonesia, Pakistan, and Turkey are other countries being considered for further trials.[10]
Manufacturing
In December, Walvax started constructing a facility to produce 120 million doses of the vaccine each year.[11]
References
- ↑ 1.0 1.1 1.2 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 2.0 2.1 2.2 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
40px | Scholia has a profile for [[:toolforge:scholia/Lua error in Module:WikidataIB at line 2818: attempt to index field 'wikibase' (a nil value).|Lua error in Module:Wd at line 405: invalid escape sequence near '"^'. (Lua error in Module:WikidataIB at line 2818: attempt to index field 'wikibase' (a nil value).)]]. |
Development | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||||||||
Administration | |||||||||||||||||
Vaccines |
|
||||||||||||||||
Controversy | |||||||||||||||||
See also | |||||||||||||||||
|
- Articles with short description
- Use dmy dates from April 2021
- Articles with invalid date parameter in template
- Chemical articles with unknown parameter in Infobox drug
- Drugs that are a vaccine
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Pages with broken file links
- Interlanguage link template link number
- Clinical trials
- COVID-19 vaccines
- Medical responses to the COVID-19 pandemic
- RNA vaccines
- Science and technology in China